BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31546897)

  • 1. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization.
    Sun NY; Chen YL; Wu WY; Lin HW; Chiang YC; Chang CF; Tai YJ; Hsu HC; Chen CA; Sun WZ; Cheng WF
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.
    Liu Z; Zhou H; Wang W; Fu YX; Zhu M
    Oncoimmunology; 2016 Jun; 5(6):e1147641. PubMed ID: 27471615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
    Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
    Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
    Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
    Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.
    Mkrtichyan M; Chong N; Abu Eid R; Wallecha A; Singh R; Rothman J; Khleif SN
    J Immunother Cancer; 2013; 1():15. PubMed ID: 24829751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
    Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
    J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.
    Lee HH; Hong SH; Rhee JH; Lee SE
    Transl Cancer Res; 2022 Jun; 11(6):1595-1602. PubMed ID: 35836530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
    Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
    Wang X; Li X; Ito A; Sogo Y; Ohno T
    Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.